IMI Stakeholder Forum 2018

Start Date 24/10/2018
Brussels, Belgium

The IMI Stakeholder Forum 2018 took place on Wednesday 24 October in Brussels at Hotel Crowne Plaza Le Palace. The theme this year was ’The value of cross-sectoral health research and innovation’. The event also offered an opportunity to celebrate IMI’s 10th anniversary


This year we looked at IMI through the lens of cross-sector collaboration, and discussed the added value of technology convergence to address complex health challenges, especially in those areas where there is huge public health need.

IMI has already attracted other industries and funders to collaborate as part of a new ecosystem for health research. To date, 24 companies from sectors such as medical technologies, diagnostics, imaging and digital have joined EFPIA as Partners in Research with the sole aim of participating in IMI. In addition, 15 Associated Partners have joined IMI, including BMGF, JDRF, the Wellcome Trust, Autism Speaks, and Simons Foundation. The IMI Associated Partners have collectively contributed around EUR 100 million to our projects in areas such as diabetes, infectious disease, and autism. Furthermore, 2017 saw the launch of the first IMI Call topic led by BioMerieux and involving 5 diagnostic companies. The time has therefore come to take a step further and decide collectively on how best to combine the knowledge within academia, different industrial sectors, health technology assessment (HTA) bodies, regulators, patient groups and public health authorities to impact health systems.

During the morning, we looked into the future. We discussed where we could collectively collaborate, and who we need in the IMI partnership to contribute to delivering the impact expected from EU citizens, knowing that working in silos -each trying to prove value for a particular part of the ecosystem- is doomed to failure.

In the afternoon, we started by looking at ways to embrace technology convergence to optimise health research, before focusing in on the neurological disease area to see how we can collectively apply the collaborative approach in practice to make a real difference to patients and healthcare systems.

Outline of the event and presentations

When no single sector can address our current health challenges. The value of cross-sectoral health research

Addressing the future of healthcare now

Convergence: a must and a choice

Panel discussion: Paths towards cross-sectoral industry collaboration in health research

  • Nicole Denjoy, Secretary General, European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry (COCIR) 
  • Elena Bonfiglioli, Regional Business Leader Health and Life Sciences EMEA Microsoft
  • Philippe Cleuziat, Innovation Program Senior Director, BioMérieux
  • Auvo Kaikkonen, Senior Life Science Specialist, European Investment Bank
  • Claire Skentelbery, Director General, Nanotechnology Industries Association
  • Joanna Wills, Research Manager UK & Ireland, GE Healthcare
    Video recording

Panel discussion: Strengthening cross-sectoral collaboration in research for higher impact on the health system  

  • Thomas Metcalfe, Strategic Innovation Leader, Roche
  • Corinne de Vries, Head of Science and Innovation Support, European Medicines Agency
  • Tsveta Schyns-Liharska, European Network for Research on Alternating Hemiplegia
  • Mairead O'Driscoll, ICPerMed Chair, Health Research Board
  • Andreas Lymberis, Head of Sector "Wearables & Bioelectronics", DG CNECT, European Commission
    Video recording

Panel discussion: Technology convergence in clinical trials

  • Bruce Magill, Director of Business Development, Personalised Medicine & Connected Health, SAP Health
  • Dipak Kalra, President, European Institute for Innovation through Health Data
  • Kimberly Hawkins, PL Head Rare Disease, Sanofi
  • Nicola Bedlington, Secretary General, European Patients' Forum
    Video recording

Case study (panel discussion): how to apply Technology convergence in safety

  • Salah-Dine Chibout, Global Head Therapeutic Areas in Preclinical Safety, Novartis
  • Jos Joore, Managing Director, Mimetas
  • Philippe Detilleux, Global Deputy, Preclinical safety, Sanofi
  • Martin FitzGerald, Deputy Director General, European Healthcare Distribution Association (GIRP)
  • Ferran Sanz, Director, Research Programme on Biomedical Informatics, GRIB
    Video recording

Setting the scene - presentation by Ferran Sanz

Case study (panel discussion): Technology convergence in the neurological disease space

  • Philippe Amouyel, Professor of Epidemiology and Public Health
  • Luc Truyen, Global Head- Development and External Affairs-Neuroscience, Johnson & Johnson
  • Gunnar Krueger, Scientific Partnerships Europe, Middle East, Africa (EMEA), Head Technology and Innovation Management, Siemens Healthineers
  • Rebecca Fuller, Director, Clinical Outcomes, CHDI Foundation
  • Patrick Burke, Patient participant from RADAR-CNS studies
    Video recording

Setting the scene - presentation by Luc Truyen

Conclusion and way forward

  • Khalil Rouhana, Deputy Director-General for Communications Networks, Content and Technology, European Commission
  • Andrzej Rys, Director responsible for Health systems, medical products and innovation, Directorate-General for Health and Food Safety, European Commission
  • Salah-Dine Chibout, Global Head Therapeutic Areas in Preclinical Safety, Novartis
  • Wolfgang Burtscher, Deputy Director-General, DG Research and Innovation, European Commission
    Video recording


Please find here the agenda.